Chicago – December 30, 2025
Drugmakers across the United States have raised list prices on around 350 prescription medicines at the start of 2026, defying mounting political pressure from President Donald Trump to curb rising healthcare costs.
The increases affect a wide range of treatments, including drugs for chronic conditions such as diabetes, cancer and autoimmune disorders, many of which are already among the most expensive therapies on the market.
Industry analysts say most hikes fall within the typical annual range of 5% to 10%, but warn that even modest list price increases can translate into higher out‑of‑pocket costs for patients with high‑deductible plans or coinsurance tied to list prices.
The moves come as the Trump administration signals a tougher stance on drug pricing, exploring executive actions and regulatory changes to link U.S. prices more closely to those in other developed markets. Drugmakers argue higher prices are needed to fund innovation, while critics say the pattern highlights the need for deeper reforms.
